| Indicator | Current Period | Same Period Last Year | YoY |
|---|---|---|---|
| Revenue | ¥55.6B | ¥45.3B | +22.6% |
| Operating Income | ¥9.5B | ¥1.7B | +450.5% |
| Ordinary Income | ¥10.2B | ¥2.0B | +402.5% |
| Net Income | ¥8.6B | ¥1.9B | +792.1% |
| ROE | 7.8% | 1.5% | - |
For FY2026 Q3, Revenue was ¥55.6B (¥45.3B in the same period last year, +¥10.3B, +22.6%), Operating Income was ¥9.5B (¥1.7B in the same period last year, +¥7.8B, +450.5%), Ordinary Income was ¥10.2B (¥2.0B in the same period last year, +¥8.2B, +402.5%), and Net Income was ¥8.6B (¥1.9B in the same period last year, +¥6.7B, +351.6%), achieving higher revenue and a significant increase in profit. The Operating Margin expanded by about 1,330bp to 17.1% (3.8% in the same period last year), with operating leverage materializing through improved Gross Margin and SG&A efficiency. The revenue plan progress rate of 77% reached the highest level in the past four years, and the buildup of orders and stabilization of monthly revenue underpin the improved earnings structure.
[Revenue] Revenue maintained high growth at ¥55.6B (+22.6%). The Business Produce Business led with ¥47.6B (+25%), supported by the ramp-up of newly hired talent and the scaling-up of clients. The acquisition of long-term projects centered on T&A themes contributed to qualitative improvement in revenue, with monthly revenue exceeding an average of ¥5B at the highest level ever since FY2026 began. The Incubation Business was ¥7.9B (+9%). The revenue plan progress rate of 77% improved significantly from 48% in the same period last year, with an accelerated buildup of backlog.
[Profit and Loss] Gross Profit was ¥27.8B (Gross Margin 50.0%, 47.2% in the same period last year, +280bp), indicating enhanced value creation capability. SG&A was ¥18.3B, down in absolute terms from ¥19.7B in the same period last year, and the SG&A ratio declined to 32.9% (43.4% in the same period last year, -1,050bp). Fixed costs turned negative relative to sales growth, and clear operating leverage emerged, resulting in Operating Income of ¥9.5B (+450.5%) and an Operating Margin of 17.1% (+1,330bp), a significant improvement. On the non-operating side, there was a positive contribution from Interest Income of ¥0.3B and FX gains of ¥0.1B, but the impact was limited, and the expansion of Ordinary Income to ¥10.2B (+402.5%) and an Ordinary Income Margin of 18.3% (+1,380bp) is attributable to improved profitability in the core business. Although tax expense increased to ¥1.4B (effective tax rate 15.8%, 9.0% in the same period last year), Net Income improved significantly to ¥8.6B (+351.6%), with a Net Margin of 15.6% (2.1% in the same period last year, +1,350bp). As a one-off factor, one impairment loss was recorded in the Incubation Business in Q3; however, the gap between Ordinary Income and Net Income is small, and the quality of earnings is sound. In conclusion, performance is trending with higher revenue and a significant increase in profit, with the turnaround to profitability in the Business Produce Business and the absolute decline in SG&A being the main drivers of P&L improvement.
[Business Produce (Consulting)] Revenue of ¥47.6B and Operating Income of ¥13.7B; the core business accounting for 85.7% of total company revenue. The same period last year had an operating loss of ¥2.2B, with Operating Income improving by ¥15.9B to achieve a turnaround to profit. Newly hired talent ramped up and clients scaled up, with contributions from the acquisition of long-term projects in T&A themes. The Operating Margin of 28.8% demonstrates high profitability and is the main driver of the company’s profit growth. The revenue plan progress rate of 77% reached a record-high level, and the stabilization of monthly revenue underpins the qualitative improvement in earnings.
[Incubation (Operating Investment)] Revenue of ¥7.9B and Operating Income of ¥3.8B; comprising 14.3% of total company revenue. Operating Income decreased by ¥0.3B (-7%) YoY, with one impairment recorded in Q3. One sale and income from investee funds contributed, but impairment compressed profits. The company holds unrealized gains of ¥2.8B against a book value of ¥2.2B, and future harvesting opportunities are expected to contribute to performance. While the Operating Margin is 48.1%, making it a highly profitable segment, revenue volatility is high and stability remains an issue.
The disparity in profitability between segments is notable; while Incubation shows a high profit margin, improvements in profitability and stability in Business Produce form the foundation for sustainable growth in company-wide performance.
Profitability: ROE 7.9% (3.0% in the prior year), Operating Margin 17.1% (3.8% in the prior year), Net Margin 15.6% (2.1% in the prior year) Cash Quality: Operating Cash Flow (OCF) is not disclosed. With an increase in Accounts Receivable (¥1.69B, ¥1.58B in the same period last year) and a lengthening of DSO to 111 days, OCF/Net Income is likely below 1.0x, requiring monitoring of the cash backing of profits Investment Efficiency: Total Asset Turnover 0.39x (0.29x in the prior year), reflecting an asset-aggregated structure while improving with sales growth Financial Soundness: Equity Ratio 78.2% (83.0% in the prior year), Current Ratio 846.4% (935.6% in the prior year), indicating extremely sound conditions. Debt-to-Equity ratio of 0.28x maintains a conservative financial structure
Operating CF: Not disclosed, but Accounts Receivable increased to ¥1.69B (¥1.58B in the same period last year, +¥0.11B), and DSO lengthened to 111 days (93 days in the prior year). The collection cycle has been delayed relative to sales growth, and OCF/Net Income is likely below 1.0x, indicating weak cash backing for profits. Other current liabilities +¥0.29B and accrued income taxes +¥0.12B partially offset funding needs.
Investing CF: Not disclosed, but intangible assets decreased by ¥0.01B due to natural decline from amortization, with limited materiality and no signs of large-scale capital expenditures.
Financing CF: Cash and deposits decreased to ¥4.02B (¥5.66B in the prior year, -¥1.64B), and equity compressed to ¥11.02B (¥13.16B in the prior year, -¥2.14B). The primary factor was the payment of the prior fiscal year-end dividend of ¥3.0B, making shareholder returns the main source of cash outflow. Short-term investments also decreased to ¥4.49B (¥5.00B in the prior year, -¥0.51B), drawing down part of liquidity.
FCF: Not disclosed, but given limited OCF generation and large dividend payments, FCF is inferred to be negative or slightly positive.
Cash Generation Assessment: Requires monitoring. While profit margins improved significantly, cash conversion is delayed due to receivables buildup, and high levels of shareholder returns are pressuring liquidity. Short-term payment capacity is extremely ample, but sustainable cash generation requires improvements in the collection cycle and appropriate normalization of return levels.
Ordinary Income ¥10.2B vs Net Income ¥8.6B: the gap is ¥1.6B (15.7%), mainly due to tax expense of ¥1.4B, with limited impact from one-off factors. Although one impairment loss was recorded in the Incubation Business in Q3, the difference between Ordinary Income and Net Income is small, suggesting the impairment was minor in scale. Non-operating income totals ¥0.4B (Interest Income ¥0.3B and FX gains ¥0.1B; 0.7% of Revenue), with low materiality, and profits mainly stem from core operations. OCF is likely to fall below Net Income (due to longer DSO and increased receivables), warranting caution regarding profit cash conversion. With increased accruals, quality of earnings has somewhat declined, and future collection trends will determine the quality of profits.
Full-year outlook revised upward to Revenue of ¥63–¥66B and Operating Income of ¥5–¥8B. Cumulative through Q3, Revenue reached ¥55.6B and Operating Income ¥9.5B, with progress rates of 84–88% for revenue (exceeding the standard progress of 75%) and 119–190% for operating income (far exceeding the standard progress of 75%), indicating extremely favorable performance. Versus standard progress, this represents an overrun of +9–13pt on revenue and +44–115pt on operating income, suggesting a high likelihood of full-year achievement even with limited incremental contribution in Q4. The background to the forecast revision is that the quality of revenue and profitability exceeded expectations due to the ramp-up of newly hired talent and scaling-up of clients in the Business Produce Business. The revenue plan progress rate of 77% has reached the highest level in the past four years, with an accelerated buildup of backlog. The reason progress rates far exceed the standard includes the stabilization of monthly revenue at a record-high average of over ¥5B since FY2026 began, with the acquisition of long-term projects contributing to the smoothing of revenue.
Year-end dividend increased by ¥0.3B to a total of ¥1.3B (¥137 per share). Combined with the Q2 interim dividend of ¥106, the annual dividend is expected to be ¥243 per share. Against cumulative Q3 Net Income of ¥8.6B, the estimated total dividends are roughly ¥2.3B (¥243 × based on shares outstanding), implying a Payout Ratio of approximately 267%, a high level. Including the payment of the prior fiscal year-end dividend of ¥3.0B, total shareholder returns over the past 12 months amount to approximately ¥5.3B, with an estimated Payout Ratio exceeding 600%, substantially above profits. Dividend resources depend on ample equity (¥11.02B) and liquidity (cash ¥4.02B, short-term investments ¥4.49B), and while there are no issues with short-term payment capacity, continuation at the same level would raise concerns about the erosion of equity and constraints on growth investment capacity. The full-year dividend outlook of ¥137 (year-end) suggests normalization of levels, and if it signals a move toward normalizing the Payout Ratio (to 60% or below), it can be evaluated as a normalization of capital policy.
[Short Term] Trends in receivables collection in Q4 and potential to shorten DSO. Finalization of full-year Payout Ratio and disclosure of next year’s return policy. Year-end actual number of Business Producers (tracking at 164 versus a plan of 180) and progress in accelerating hiring. Harvesting opportunities in the Incubation Business (timing of realizing ¥2.8B in unrealized gains).
[Long Term] Progress toward the mid-term targets of doubling Revenue in five years (CAGR 15%) and maintaining an Operating Margin of 15% or higher. Expanded acquisition of large clients utilizing Industrial Produce & Business Eco-cycle building. Implementation and execution of revenue models incorporating investment schemes (e.g., success fees). Enhanced talent development systems and productivity gains through knowledge and infrastructure development. Expansion of an end-to-end support model driving from strategy development through accompaniment, execution, and realization, and deepening of the customer base.
[Position within Industry] (Reference information / Our compilation)
Although the company’s industry classification is primarily consulting, the benchmark is compared with the healthcare industry (healthcare, N=56 companies, 2025-Q3).
Profitability: ROE 7.9% (+1.4pt above the industry median of 6.5%), Operating Margin 17.1% (+10.0pt above the industry median of 7.1%, at the upper tier within the industry), Net Margin 15.6% (+10.3pt above the industry median of 5.3%, among the top tier in the industry). Profitability is extremely high within the industry, reflecting a high value-added business model.
Growth: Revenue growth rate 22.6% (+13.5pt above the industry median of 9.1%, upper tier within the industry). Over the past five periods, growth has remained high at 22.6%, significantly outpacing the industry average expansion trend.
Efficiency: Total Asset Turnover 0.39x (0.42pt below the industry median of 0.81x). Reflecting an asset-aggregated structure with a high ratio of cash and marketable securities, turnover is in the lower tier within the industry. DSO 111 days (+53 days above the industry median of 57.9 days, longer), and while operating working capital days are not disclosed, delays in the collection cycle are weighing on efficiency.
Soundness: Equity Ratio 78.2% (+21.1pt above the industry median of 57.1%, upper tier within the industry), Current Ratio 846.4% (+616pt above the industry median of 230%, top tier within the industry). Financial soundness is extremely high, with substantial room in short-term payment capacity.
Overall: Profitability and soundness are among the top tier within the industry, establishing a high value-added, low-risk business model. On the other hand, asset efficiency is in the lower tier, and utilizing liquidity and improving the collection cycle are challenges going forward. Growth is significantly above the industry average, maintaining a sustainable expansion trend.
Industry: Healthcare (56 companies), Comparison: 2025 Q3, Source: Our compilation
The prolongation of receivables collection (DSO 111 days, 93 days in the prior year) is delaying operating cash generation, weakening the cash backing of profits. The receivables balance of ¥1.69B is equivalent to 30.4% of Revenue, and if uncollectibility risk materializes, the impact would be roughly equivalent to about 1.8 years of Operating Income. The Incubation Business exhibits high revenue volatility, and Operating Income fluctuates depending on the timing of impairments and disposals. One impairment was recorded in Q3, and the timing of harvesting ¥2.8B in unrealized gains will significantly impact performance. The Payout Ratio is an estimated approximately 267% (annual), and including total returns over the past 12 months exceeds about 600%, well above profits. Although liquidity is ample, continuation at the same level could lead to erosion of equity (¥11.02B, down ¥2.14B from ¥13.16B in the prior year) and constraints on growth investment capacity.
Operating leverage materialized, driving a significant improvement in the Operating Margin to 17.1%, and the ramp-up of newly hired talent and scaling-up of clients indicate a shift in the earnings structure. The revenue plan progress rate of 77% and the stabilization of monthly revenue underpin the accelerated buildup of backlog, and the turnaround to profitability in the Business Produce Business forms the foundation for sustainable growth going forward. On the other hand, the lengthening of DSO to 111 days and the high Payout Ratio of about 267% are key themes regarding pressure on cash generation and equity. Liquidity is extremely ample and short-term payment capacity is rock-solid, but improving the collection cycle and normalizing return levels are keys to sustainable growth. If normalization of the full-year dividend outlook is confirmed, it will be a positive factor in evaluating the soundness of capital policy.
This report is an automatically generated earnings analysis document created by AI through integrated analysis of XBRL financial statement data and PDF financial presentation materials. It does not constitute a recommendation to invest in any specific security. The industry benchmark is reference information compiled by our company based on publicly available financial data. Investment decisions are your own responsibility; please consult a professional as needed before making any investment decisions.